PrEP initiation, persistence, and adherence during pregnancy through the postpartum period: a prospective analysis in Kenya
Participants were offered PrEP during their 2nd trimester and followed through 9-months postpartum. At the end of the study, 58% of PrEP initiators self-reported persistence of use, and 50% of randomly selected DBS had quanitfiable TFV-DP. Having quantifiable TFV-DP was twice as likely during pregnancy than postpartum, and having a partner known to be living with HIV was the strongest predictor of PrEP initiation, persistence, and quantifiable TFV-DP.
Resource Details
- Study Type
- Observational study
- Year
- 2023
- Population
- HIV-uninfected women, Pregnant Women
- Author
- Pintye J, Kinuthia J, Abuna F, Anderson PL, Dettinger JC, Gomez L, Haberer JE, Marwa MM, Ngumbau N, Omondi P, Odhiambo B, Stern J, Watoyi S, Baeten JM, John-Stewart G.
More Publications & Resources
Standard Operating Procedure for Injectable Lenacapavir as Pre-exposure Prophylaxis
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Site/Facility Readiness Assessment Tool to Support Lenacapavir for HIV Prevention Introduction
Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People
Tools for Active Safety Surveillance of Maternal and Infant Health Outcomes for Pregnant and Breastfeeding Users of Oral PrEP and PrEP Ring
Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions
Assessment of Facility Readiness for PrEP Provision in Antenatal and Postnatal Care Services
Oral PrEP for PBFP Training Package
Key Considerations for Integration of PrEP for Pregnant and Breastfeeding People into National Prevention of Vertical Transmission Polices
No results found.